# US 2022/0008339 A1 · Embolic microspheres and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008339 A1
- Document ID: US20220008339A1
- Status: Published application
- Kind: A1
- Application number: 17/484,110
- Filed: 2021-09-24
- Published: 2022-01-13
- Earliest claimed: 2019-03-22
- Assignees: Biocompatibles UK Limited; The Johns Hopkins University
- Applicants: Biocompatibles UK Limited; The Johns Hopkins University
- Inventors: Matthew R. Dreher; Clifford Weiss
- Web page: https://patentgrep.com/patent/US20220008339A1

## CPC

- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

This present disclosure relates to compositions and methods useful in therapeutic embolisation and particularly in methods for bariatric arterial embolisation (BAE).

## Claims

### Claim 1

A method of bariatric arterial embolisation, comprising delivering to a blood vessel supplying a gastric fundus of a subject, an effective amount of a composition comprising a population of polymeric microspheres comprising a polymer and having a native size distribution in which not more than 10% of the microspheres have a diameter of less than 120 μm and not more than 10% of the microspheres have a diameter greater than 200 μm.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the microspheres are delivered by a transcatheter route.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the microspheres have a mean compression modulus of greater than 1000 kPa.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the microspheres have a mean compression modulus of at least 5 times that of Bead Block® 300-500.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the microspheres have a native size distribution in which not more than 5% of the microspheres have a diameter less than 100 μm and not more than 5% of the microspheres have a diameter greater than 200 μm.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the microspheres have a native size distribution such that not more than 5% of the microspheres have a diameter less than 120 μm and not more than 10% of the microspheres have a diameter greater than 185 μm.

### Claim 7 (depends on 1)

The method according to claim 1, wherein not more than 10% of the microspheres have a penetration value, in a swine kidney model, of less than 80 μm.

### Claim 8 (depends on 1)

The method according to claim 1, wherein not more than 10% of the microspheres have a penetration value of greater than 300 μm.

### Claim 9 (depends on 1)

The method according to claim 1, wherein not more than 5% of the microspheres have a penetration value of less than 80 μm and not more than 5% of the microspheres have a penetration value of greater than 300 μm.

### Claim 10 (depends on 1)

The method according to claim 1, wherein not more than 5% have a penetration value of less than 90 μm and not more than 5% of the microspheres have a penetration value of greater than 250 μm.

### Claim 11

A method of inducing weight loss or of slowing weight gain in a subject in need thereof, comprising delivering to a blood vessel supplying a gastric fundus of the subject, an effective amount of a composition comprising a population of polymeric microspheres comprising a polymer and having a native size distribution in which not more than 10% of the microspheres have a diameter of less than 120 μm and not more than 10% of the microspheres have a diameter greater than 200 μm.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the microspheres are delivered by the transcatheter route.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the microspheres have a mean compression modulus of greater than 1000 kPa.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the microspheres have a native size distribution in which not more than 5% of the microspheres have a diameter less than 100 μm and not more than 5% of the microspheres have a diameter greater than 200 μm.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the microspheres have a native size distribution such that not more than 5% of the microspheres have a diameter less than 120 μm and not more than 10% of the microspheres have a diameter greater than 185 μm.

### Claim 16 (depends on 11)

The method according to claim 11, wherein not more than 10% of the microspheres have a penetration value, in a swine kidney model, of less than 80 μm.

### Claim 17 (depends on 11)

The method according to claim 11, wherein not more than 10% of the microspheres have a penetration value of greater than 300 μm.

### Claim 18 (depends on 11)

The method according to claim 11, wherein not more than 5% of the microspheres have a penetration value of less than 80 μm and not more than 5% of the microspheres have a penetration value of greater than 300 μm.

### Claim 19 (depends on 11)

The method according to claim 11, wherein not more than 5% have a penetration value of less than 90 μm and not more than 5% of the microspheres have a penetration value of greater than 250 μm.

### Claim 20

A method for the treatment of obesity in a subject in need thereof, comprising delivering to a blood vessel supplying a gastric fundus of the subject, an effective amount of a composition comprising a population of polymeric microspheres comprising a polymer and having a native size distribution in which not more than 10% of the microspheres have a diameter of less than 120 μm and not more than 10% of the microspheres have a diameter greater than 200 μm.
